161 related articles for article (PubMed ID: 31015757)
1. Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis.
Tang B; Wang J; Luo LL; Li QG; Huang D
Int J Chron Obstruct Pulmon Dis; 2019; 14():757-766. PubMed ID: 31015757
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
Perrone V; Sangiorgi D; Buda S; Degli Esposti L
Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
[TBL] [Abstract][Full Text] [Related]
3. Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist.
Yang HH; Lai CC; Wang YH; Yang WC; Wang CY; Wang HC; Chen L; Yu CJ
Int J Chron Obstruct Pulmon Dis; 2017; 12():2477-2485. PubMed ID: 28860742
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Budesonide/Formoterol with Budesonide, Formoterol or Placebo for Stable Chronic Obstructive Pulmonary Disease: A Meta-Analysis.
Tang B; Wang J; Luo LL; Li QG; Huang D
Med Sci Monit; 2019 Feb; 25():1155-1163. PubMed ID: 30747109
[TBL] [Abstract][Full Text] [Related]
5. The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials.
Eriksson G; Calverley PM; Jenkins CR; Anzueto AR; Make BJ; Lindberg M; Fagerås M; Postma DS
Int J Chron Obstruct Pulmon Dis; 2017; 12():1457-1468. PubMed ID: 28553098
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
Kerwin EM; Siler TM; Arora S; Darken P; Rose E; Reisner C
Int J Chron Obstruct Pulmon Dis; 2018; 13():1483-1494. PubMed ID: 29773947
[TBL] [Abstract][Full Text] [Related]
7. Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.
Calverley PM; Eriksson G; Jenkins CR; Anzueto AR; Make BJ; Persson A; Fagerås M; Postma DS
Int J Chron Obstruct Pulmon Dis; 2017; 12():13-25. PubMed ID: 28031707
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
Kim SW; Rhee CK; Kim YJ; Lee S; Kim HJ; Lee JW
Respir Res; 2016 May; 17(1):63. PubMed ID: 27229850
[TBL] [Abstract][Full Text] [Related]
9. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
[TBL] [Abstract][Full Text] [Related]
10. Risk of pneumonia with budesonide-containing treatments in COPD: an individual patient-level pooled analysis of interventional studies.
Hollis S; Jorup C; Lythgoe D; Martensson G; Regnell P; Eckerwall G
Int J Chron Obstruct Pulmon Dis; 2017; 12():1071-1084. PubMed ID: 28435240
[TBL] [Abstract][Full Text] [Related]
11. Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids.
Huang TM; Kuo KC; Wang YH; Wang CY; Lai CC; Wang HC; Chen L; Yu CJ;
BMC Infect Dis; 2020 Sep; 20(1):706. PubMed ID: 32977747
[TBL] [Abstract][Full Text] [Related]
12. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
Nannini L; Cates CJ; Lasserson TJ; Poole P
Cochrane Database Syst Rev; 2004; (3):CD003794. PubMed ID: 15266502
[TBL] [Abstract][Full Text] [Related]
13. Metabolic changes of different high-resolution computed tomography phenotypes of COPD after budesonide-formoterol treatment.
Wang C; Li JX; Tang D; Zhang JQ; Fang LZ; Fu WP; Liu L; Dai LM
Int J Chron Obstruct Pulmon Dis; 2017; 12():3511-3521. PubMed ID: 29255358
[TBL] [Abstract][Full Text] [Related]
14. The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study.
Wang CY; Lai CC; Yang WC; Lin CC; Chen L; Wang HC; Yu CJ
Int J Chron Obstruct Pulmon Dis; 2016; 11():2775-2783. PubMed ID: 27877031
[TBL] [Abstract][Full Text] [Related]
15. A score to predict short-term risk of COPD exacerbations (SCOPEX).
Make BJ; Eriksson G; Calverley PM; Jenkins CR; Postma DS; Peterson S; Östlund O; Anzueto A
Int J Chron Obstruct Pulmon Dis; 2015; 10():201-9. PubMed ID: 25670896
[TBL] [Abstract][Full Text] [Related]
16. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
17. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
Nannini L; Lasserson TJ; Poole P
Cochrane Database Syst Rev; 2003; (4):CD003794. PubMed ID: 14583994
[TBL] [Abstract][Full Text] [Related]
18. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
Spencer S; Evans DJ; Karner C; Cates CJ
Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
[TBL] [Abstract][Full Text] [Related]
19. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
[TBL] [Abstract][Full Text] [Related]
20. Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists.
Wang CY; Lin YS; Wang YH; Lai CC; Wang HC; Chen L; Yu CJ;
Aging (Albany NY); 2019 Sep; 11(17):6863-6871. PubMed ID: 31509517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
